Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

Senator John Cornyn recognizes facility's role in advancing radiation countermeasures for cancer patients and U.S. warfighters; Mayor Gina Ortiz Jones, Office of Senator Cornyn, and Velocity Bioworks leadership join Valion Bio at ribbon cutting ceremony SAN ANTONIO, May 6, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for acute radiation syndrome, oncology supportive care, and longevity indications, today celebrated the grand opening of its wholly-owned biomanufacturing subsidiary, Velocity Bioworks, at a ribbon-cutting ceremony in San Antonio. The facility, located on the VelocityTX innovation campus on San Antonio's historic East Side, marks the formal activation of the company's vertically integrated manufacturing strategy and positions Valion Bio as one of the few clinical-stage biotechs with end-to-end domestic biomanufacturing capability for its lead asset.